Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80–85% of lung cancer cases. It develops when abnormal cells in the lung grow uncontrollably and can spread to nearby tissues or other parts of the body. NSCLC includes several different types, mainly adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because each type can behave differently, accurate diagnosis and molecular testing are important for selecting the most appropriate treatment.

What Is Non-Small Cell Lung Cancer?

NSCLC is a group of lung cancers that generally grow and spread differently from small cell lung cancer. Adenocarcinoma is the most frequently diagnosed subtype and can occur in both smokers and people who have never smoked.small-cell-lung-carcinoma Squamous cell carcinoma is strongly associated with smoking and often develops near the larger airways. Large cell carcinoma is less common and may grow relatively quickly.

NSCLC can begin in one area of the lung and, if untreated, potentially spread to lymph nodes, the opposite lung, bones, liver, brain or other organs. Early detection can provide more treatment options and may improve outcomes.

Symptoms of Non-Small Cell Lung Cancer

In its early stages, NSCLC may cause few or no noticeable symptoms. Some lung cancers are discovered incidentally during imaging performed for another reason. When symptoms occur, they may include:

• Persistent or worsening cough

• Coughing up blood

• Shortness of breath

• Chest discomfort or pain

• Wheezing

• Recurrent respiratory infections

• Unexplained weight loss

• Loss of appetite

• Persistent fatigue

• Hoarseness

Symptoms can vary considerably depending on the location and size of the tumor and whether the cancer has spread.small-cell-lung-carcinoma Persistent respiratory symptoms should be evaluated by a qualified medical professional, particularly in people with a history of smoking or other risk factors.

Risk Factors

Smoking is the most important preventable risk factor for lung cancer. However, NSCLC can also develop in people who have never smoked.

Other potential risk factors include exposure to second-hand smoke, radon, asbestos and certain workplace chemicals or pollutants. Increasing age and a personal or family history of lung cancer may also increase risk. In some patients, specific genetic changes within cancer cells can drive tumor growth even when there is no significant smoking history.

Avoiding tobacco, reducing exposure to known carcinogens and discussing appropriate screening with a healthcare professional are important steps for people at increased risk.

How Is NSCLC Diagnosed?

Diagnosis usually begins with a medical history, physical examination and imaging. A chest CT scan can provide detailed information about a suspicious lung lesion, while PET-CT may help assess whether cancer has spread.

A definitive diagnosis generally requires examination of tumor tissue or cells. Depending on the location of the lesion, a sample may be obtained through bronchoscopy, EBUS, CT-guided biopsy or another biopsy procedure.

Pathology testing determines the type of lung cancer. Additional molecular testing can identify genetic alterations that may influence treatment decisions. small-cell-lung-carcinoma Depending on the clinical situation, testing may include alterations involving EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK and other biomarkers. PD-L1 testing may also help determine whether immunotherapy is appropriate.

Stages of Non-Small Cell Lung Cancer

NSCLC is generally staged from Stage I to Stage IV.

Stage I: The cancer is relatively small and remains within the lung.

Stage II: The tumor may be larger or may involve nearby lymph nodes or structures.

Stage III: The cancer involves more extensive nearby lymph nodes or surrounding structures but may still be potentially treatable with curative intent in selected patients.

Stage IV: The cancer has spread to distant parts of the body. This is called metastatic NSCLC.

Staging is essential because treatment depends heavily on the size and location of the tumor, lymph-node involvement, distant spread, overall health and molecular characteristics of the cancer.

Treatment Options

Treatment for NSCLC is individualized. For early-stage disease, surgery may be recommended to remove the tumor and affected portion of the lung. Some patients may also receive chemotherapy, immunotherapy or targeted therapy before or after surgery.

For selected patients who cannot undergo surgery, stereotactic body radiation therapy (SBRT) may be an effective treatment for localized tumors.

Locally advanced NSCLC may require a combination of chemotherapy, radiation therapy and immunotherapy, depending on the stage and patient's overall condition.

For advanced or metastatic NSCLC, treatment may include targeted therapy, immunotherapy, chemotherapy or combinations of these treatments. If molecular testing identifies a specific actionable mutation, targeted medicines may provide an important treatment option.

Importance of Multidisciplinary Care

Management of NSCLC often involves several specialists, including a pulmonologist, interventional pulmonologist, medical oncologist, radiation oncologist, thoracic surgeon, radiologist and pathologist. A multidisciplinary approach helps ensure that diagnosis, staging and treatment decisions are coordinated.

Advanced bronchoscopic procedures such as EBUS-TBNA can be particularly useful for sampling mediastinal lymph nodes and helping establish an accurate stage in appropriate patients.

When Should You See a Specialist?

A persistent cough, unexplained breathlessness, coughing up blood, recurrent chest infections or an abnormal lung lesion on imaging should not be ignored. Early evaluation can help determine whether further imaging, bronchoscopy, biopsy or other investigations are necessary.

If you or a family member has been diagnosed with NSCLC, treatment should be discussed with a qualified lung cancer or pulmonary specialist and oncology team. The best treatment depends on the individual cancer's stage, pathology, molecular profile and overall health.